BASKING RIDGE, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for the three months and nine months ended September 30, 2018 .
Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache BASKING RIDGE, N.J. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc.,
BASKING RIDGE, N.J. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the third quarter ended September 30, 2018 after the close of trading on Tuesday,
BASKING RIDGE, N.J. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Ardelle Ferris to a new position within the company, Vice President of Managed Care.
– Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache – Basking Ridge, NJ, October 22, 2018 – electroCore, Inc.
BASKING RIDGE, N.J. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Cantor Global Healthcare Conference in New York, NY .
BASKING RIDGE, N.J. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that seven abstracts and an oral presentation featuring non-invasive vagus nerve stimulation (nVNS) across two primary headache disorders
BASKING RIDGE, N.J. , Aug. 13, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for the three month and six months ended June 30, 2018 . Second Quarter 2018 and Recent Highlights Second
BASKING RIDGE, N.J. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a research collaboration with Massachusetts General Hospital (MGH) through the company’s funding of a MGH program targeting
Innovative technology provides patients with convenient, easy-to-use treatment option without the potential side effects associated with commonly prescribed medicines BASKING RIDGE, N.J. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine